Insights

Why Novavax Stock Is Sinking Today

What happened
Shares of Novavax (NASDAQ: NVAX) were sinking 11.9% as of 10:27 a.m. ET on Tuesday after plunging as much as 21.6% earlier in the morning. Investors reacted negatively to the company’s first-quarter results announced after market close on Monday.
Novavax reported Q1 revenue of $704 million, up 57% year over year. However, the consensus estimate was for revenue of $845 million. 
The company posted its first profitable quarter ever, with Q1 earnings of $203 million, or $2.56 per share. But the average Wall Street estimate was for earnings of $2.69 per share.
So what
Anytime a company misses analysts’ top- and bottom-line estimates, its shares will almost inevitably fall. However, there’s also another concern for investors with Novavax’s Q1 update.
The vaccine maker reaffirmed its full-year 2022 revenue guidance of between $4 billion and $5 billion. But in Novavax’s Q1 conference call, management acknowledged that this range assumes the delivery of doses of the company’s NVX-Cov2373 COVID-19 vaccine to Gavi (the Vaccine Alliance) for distribution to low- and middle-income countries.
This is problematic for a couple of reasons. First, Gavi hasn’t ordered any doses so far. Second, Novavax’s management stated that Gavi intends to revise the volume and timing of any future orders. Depending on the extent of these revisions, Novavax’s full-year revenue guidance could be in jeopardy. 
Image source: Getty Images.

Now what
Despite this uncertainty, investors can look forward to potential catalysts for the vaccine stock over the near term. Most importantly, the U.S. Food and Drug Administration scheduled a meeting for an advisory committee to review Novavax’s Emergency Use Authorization filing for NVX-CoV2373 on June 7, 2022. This meeting could pave the way for the vaccine to enter the U.S. market, at long last.
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Shares of Novavax (NASDAQ: NVAX) were sinking 11.9% as of 10:27 a.m. ET on Tuesday after plunging as much as 21.6% earlier in the morning. Investors reacted negatively to the company’s first-quarter results announced after market close on Monday.

Novavax reported Q1 revenue of $704 million, up 57% year over year. However, the consensus estimate was for revenue of $845 million. 

The company posted its first profitable quarter ever, with Q1 earnings of $203 million, or $2.56 per share. But the average Wall Street estimate was for earnings of $2.69 per share.

So what

Anytime a company misses analysts’ top- and bottom-line estimates, its shares will almost inevitably fall. However, there’s also another concern for investors with Novavax’s Q1 update.

The vaccine maker reaffirmed its full-year 2022 revenue guidance of between $4 billion and $5 billion. But in Novavax’s Q1 conference call, management acknowledged that this range assumes the delivery of doses of the company’s NVX-Cov2373 COVID-19 vaccine to Gavi (the Vaccine Alliance) for distribution to low- and middle-income countries.

This is problematic for a couple of reasons. First, Gavi hasn’t ordered any doses so far. Second, Novavax’s management stated that Gavi intends to revise the volume and timing of any future orders. Depending on the extent of these revisions, Novavax’s full-year revenue guidance could be in jeopardy. 

Image source: Getty Images.

Now what

Despite this uncertainty, investors can look forward to potential catalysts for the vaccine stock over the near term. Most importantly, the U.S. Food and Drug Administration scheduled a meeting for an advisory committee to review Novavax’s Emergency Use Authorization filing for NVX-CoV2373 on June 7, 2022. This meeting could pave the way for the vaccine to enter the U.S. market, at long last.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!